ClinicalTrials.gg
RecruitingNCT07537153Updated Jul 14, 2026

Genicular Artery Embolization for Knee Osteoarthritis

An interventional study of Embosphere Microspheres in Osteoarthritis and Knee Osteoarthritis, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Primary conditionOsteoarthritis, KneeRegistry: OsteoarthritisReclassifiedWhy we changed it
Registry
Osteoarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoarthritis, Knee
Why
  1. The study's listed conditions name Osteoarthritis, Knee, a narrower term within Osteoarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Northwestern University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Osteoarthritis, Knee by Northwestern University — 3 open to participants now, 5 under way, 1 of them phase 3. Osteoarthritis, Knee · Northwestern University.

Planned enrollment
11th of 12
15 · median 50
Started
2026
the only one that year
No phase
9 of 12
2 open now
Registered
12th of 12
by date

Among the 12 studies in Osteoarthritis, Knee by Northwestern University, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 9 with no phase, and was the 12th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 12 studies in Osteoarthritis, Knee by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Osteoarthritis, Knee by Northwestern University, or all of them as a file.
02

Study summary

Patients will be asked to take part in this research study because they have mild-to-moderate knee osteoarthritis (OA) and were referred clinically for a procedure called Genicular Artery Embolization (GAE). Osteoarthritis is the most common form of arthritis. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. The symptoms of OA include pain or aching, stiffness, decreased range of motion, and swelling. The purpose of this study is to evaluate the safety and effectiveness of GAE for the treatment of knee pain attributed to OA.

Research participants will be in this research study for about 3 years. The study includes a screening visit, GAE procedure, and six follow-up visits.

At the screening visit, a review of their medical history, demographics, and medications will be collected; physical examination will be completed; knee x-ray will be done; and two questionnaires on your knee pain will be administered. The GAE procedure will involve receiving sedation or medication to help them relax, lidocaine injected under the skin in the area of the body where catheters will be inserted into one of your arteries and then using x-ray, a catheter will be directed to the arteries supplying the lining of the knee. Then tiny microspheres will be injected into the artery to decrease the blood supply to this knee joint tissue.

The follow-up visits up to 12 months will include a focused physical examination of the treated knee, documentation of medications, and two questionnaires will be administered. The follow-up visits at year 2 and 3 will include documentation of medications and any new treatments for OA as well as completion of two questionnaires. Follow-up visits maybe conducted in clinic or remotely.

03

Conditions studied

  • Osteoarthritis
  • Knee Osteoarthritis

Browse trials for

Keywords

  • Osteoarthritis
  • Knee Osteoarthritis
  • Genicular Artery Embolization
  • GAE
  • Embosphere Microspheres
  • GAE Knee
  • GAE Embosphere Microspheres
04

In context

Osteoarthritis, Knee Reclassified

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

This study's planned enrollment of 15 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.

Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.

Compared within Osteoarthritis, Knee, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-80 years
  • Mild-to-moderate knee OA as determined by radiographs demonstrating Kellgren- Lawrence grade 2-3
  • Self-reported pain of at least 5/10 VAS questionnaire
  • Failure of conservative therapy, such as pain medications, for at least 3 months
  • Patient must understand and sign the
  • Patient can comply with the proposed follow-up schedule
  • Patient can follow the post-operative management

Exclusion criteria

Exclusion Criteria:

  • History of rheumatoid arthritis
  • Renal insufficiency precluding angiography ( \< 50 mL/min)
  • Irreversible coagulopathy
  • Previous knee arthroplasty on the intended knee
  • Existing knee joint infection
  • Kellgren-Lawrence grade 1 or 4
  • Severe atherosclerosis as manifest by claudication and/or diminished peripheral pulses
  • \< 6 months
  • Infectious arthritis
  • Allergy to iodinated contrast resulting in anaphylaxis
  • Pregnant or interested in becoming pregnant three months from the date of the GAE procedure
  • Involved in litigation or worker's compensation claims
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    GAE Procedure

    All participants will undergo a procedure called Genicular Artery Embolization (GAE) that will be done to try to reduce the pain in their knees.

    Device: Embosphere Microspheres

Interventions

  • DeviceEmbosphere Microspheres

    Genicular Artery Embolization is performed by either inserting a small catheter into the artery of the upper thigh or an artery at the wrist, and with the use of x-ray, the catheter is guided to the arteries supplying the lining of the knee. Tiny particles are then injected through the catheter into these arteries, reducing the blood supply. These small particles are considered a medical device called Embosphere Microspheres. These microspheres are approved by the Food and Drug Administration (FDA) in the United States to treat hypervascular tumors; in the prostate arteries to relieve symptoms related to benign prostate hyperplasia; and to address arteriovenous malformations. The use of Embosphere Microspheres in this study is considered experimental as it has not been approved by the FDA to reduce pain associated with knee OA.

07

What researchers measure

Primary outcomes

  1. Patient safety endpoints

    Primary safety endpoints include: 1\. Incidence and severity of adverse events (AEs). These include: 1. Non-target embolization (e.g., distal leg) 2. All transient intra- and post-procedure events (e.g., skin changes) 3. Death

    Time frame: Screening/baseline, 1, 3, and 6 months

  2. Objective clinical endpoints - Cone beam computed tomography

    Change in enhancement on cone beam computed tomography (CT)

    Time frame: Immediately pre-and post-embolization

  3. Objective clinical endpoints - VAS

    Change in Visual Analogue Scale (VAS), a measurement instrument where 0 represents the minimum value (e.g., no pain) and 100 (or 10) represents the maximum value (e.g., worst imaginable pain). Consequently, higher scores indicate a worse outcome (more pain/severity), while lower scores indicate a better outcome

    Time frame: Screening/baseline, 1, 3, 6, 12, 24 and 36 months

  4. Objective clinical endpoints - WOMAC

    Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a measurement instrument designed to evaluate pain, stiffness, and physical function in patients with hip or knee osteoarthritis. Higher scores on the WOMAC indicate a worse outcome (greater pain, stiffness, and functional limitations).

    Time frame: Screening/baseline, 1, 3, 6, 12, 24 and 36 months

Secondary outcomes

  1. Preliminary Effectiveness - WOMAC

    Secondary endpoint will be evaluated based on existing validated pain scoring systems. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a measurement instrument designed to evaluate pain, stiffness, and physical function in patients with hip or knee osteoarthritis will be utilized. Higher scores on the WOMAC indicate a worse outcome (greater pain, stiffness, and functional limitations).

    Time frame: Screening/baseline, 1, 3, 6, and 12 months

  2. Preliminary Effectiveness - VAS

    Secondary endpoint will be evaluated based on existing validated pain scoring systems. The Visual Analogue Scale (VAS), a measurement instrument where 0 represents the minimum value (e.g., no pain) and 100 (or 10) represents the maximum value (e.g., worst imaginable pain) will be utilized. Consequently, higher scores indicate a worse outcome (more pain/severity), while lower scores indicate a better outcome.

    Time frame: Screening/baseline, 1, 3, 6, and 12 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Apr 2028, 21 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 21 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2026
First posted
Apr 17, 2026
StartActual
Jul 10, 2026
Primary completionEst.
Apr 10, 2028
CompletionEst.
Apr 10, 2031
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07537153
Collaborators
Northwestern Memorial Hospital
Responsible party
Robert Lewandowski (Professor of Radiology, Medicine, and Surgery; Director of Interventional Oncology, Northwestern University) — Principal investigator
First posted
Apr 17, 2026
Start date
Jul 10, 2026
Primary completion
Apr 10, 2028 (estimated)
Completion
Apr 10, 2031 (estimated)
Last update
Jul 14, 2026

Study contacts

Robert Lewandowski, MD
Contact
r-lewandowki@northwestern.edu
312-695-9121
Kristie Kennedy, MA
Contact
kristie.kennedy@northwestern.edu
312-695-4023
Robert Lewandowski, MD
principal investigator · Northwestern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion